Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation-Reference-Cited by-同舟云学术

Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation

Published:2021-10-01 Issue:5 Volume:75 Page:357-363
ISSN:2255-890X
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
language:en
Short-container-title:

Author:

Hartmane Ilona¹²,Ivdra Iveta¹²,Mikažāns Ingmārs¹²,Bondare-Ansberga Vanda¹

Affiliation:

1. Clinical Centre of Skin and Sexually Transmitted Diseases, Rīga 1st Hospital , 2 Aristīda Briāna Str., Rīga, LV-1001 , Latvia

2. Department of Dermatology and Venerology , Rīga Stradiņš University , 18 Baznīcas Str., Rīga, LV-1010 , Latvia

Abstract

Abstract Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/prolas-2021-0052

Reference45 articles.

1. Armstrong, A., Jarvis S., Boehncke, W. H., Rajagopalan, M. (2018). Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis, results of the Clear About Psoriasis worldwide survey. J. Eur. Acad., Dermatol. Venereol., 32, 2200–2207.10.1111/jdv.15065

2. Bongiorno, M. R., Pistone, G., Doukaki, S., Arico, M. (2008). Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol. Ther., 21, 15–20.10.1111/j.1529-8019.2008.00227.x

3. Caiazzo, G., Fabbrocini, G., Di Caprio, R. (2018). Psoriasis, cardiovascular events, and biologics, lights and shadows. Front Immunol., 9, 1–12.10.3389/fimmu.2018.01668

4. Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., Romanelli, M. (2018). Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci., 19 (179), 1–31.10.3390/ijms19010179

5. Chiricozzi, A., Zangrilli, A., Bavetta, M., Bianchi L. (2017). Real-life 9-year expierence with adalimumab in psoriasis and psoriatic arthritis, results of a single-centre, retrospective study. J. Eur. Acad., Dermatol. Venereol., 31, 304–311.10.1111/jdv.13771